A blood biomarker study from the INTEGRATE trial of 150 patients, showed that high plasma levels of IL8, VEGF-A and sVEGFR-1 may be adverse prognostic factors in patients with refractory advance oesophagogastric cancer treated with regorafenib (oral multi-kinase inhibitor).

Exploratory proteomics and genomics studies are ongoing.